Press Releases

Revenue Increased 26% to $210.5 Million in 2020 Compared to Prior Year Net Loss $(3.0) Million in Q4 2020 Versus Net Loss $(219.8) Million in Q4 2019 Achieved Adjusted EBITDA Goal With $2.2 Million in Q4 2020 Combination with Aphria Inc. Expected to Close in Q2 2021 to Create the World’s Largest

NANAIMO, British Columbia --(BUSINESS WIRE)--Feb. 12, 2021-- Tilray Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announced today it will report results for 2020 full fiscal year and fourth quarter ended December

Grow Pharma will distribute Tilray’s GMP-certified medical cannabis products across the UK New UK agreement gives doctors and patients access to a sustainable supply of Tilray’s pharmaceutical-grade medical cannabis products NANAIMO, British Columbia --(BUSINESS WIRE)--Feb. 9, 2021-- Tilray Inc.

Worldpharma Biotech will produce the first medical cannabis products for clinical trials in Spain with Tilray GMP-certified medical cannabis Tilray medical cannabis will now be available in 17 countries around the world NANAIMO, British Columbia --(BUSINESS WIRE)--Feb. 4, 2021-- Tilray, Inc.

With new market authorization, Tilray confirms its development in the international medical cannabis sector and its leadership position in the EMEA region Portugal will become the 16 th country where patients can access Tilray medical cannabis products NANAIMO, British Columbia --(BUSINESS

The French National Agency for the Safety of Medicines and Health Products (ANSM) Selects Tilray for First Medical Cannabis Experiment with Patients in France NANAIMO, British Columbia & PARIS--(BUSINESS WIRE)--Jan. 26, 2021-- Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production,